Lineage Cell Therapeutics (LCTX) News Today $1.20 -0.02 (-1.24%) As of 10:34 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartHeadlinesInsider TradesOwnershipSEC FilingsShort InterestBuy This Stock LCTX Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period D. Boral Capital Reaffirms Buy Rating for Lineage Cell Therapeutics (NYSEAMERICAN:LCTX)2 hours ago | marketbeat.com5 Analysts Assess Lineage Cell Therapeutics: What You Need To KnowAugust 28 at 6:38 AM | benzinga.comLineage Cell Therapeutics FY2028 EPS Cut by B. RileyAugust 20, 2025 | marketbeat.comCookson Peirce & Co. Inc. Takes $113,000 Position in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX)August 18, 2025 | marketbeat.comLineage Cell Therapeutics Q3 EPS Raised by HC WainwrightAugust 17, 2025 | marketbeat.comLineage Cell Therapeutics reports Q2 EPS (13c), consensus (3c)August 12, 2025 | msn.comLineage Cell Therapeutics, Inc. (LCTX) Q2 2025 Earnings Call TranscriptAugust 12, 2025 | seekingalpha.comLineage Cell Therapeutics (LCTX) Projected to Post Earnings on TuesdayAugust 7, 2025 | marketbeat.comLineage Cell Therapeutics (NYSEAMERICAN:LCTX) Earns Buy Rating from D. Boral CapitalAugust 6, 2025 | marketbeat.comLineage Announces Dosing of First Patient in New Clinical Study of OPC1 for Subacute and Chronic Spinal Cord InjuryAugust 5, 2025 | finance.yahoo.comLineage Cell Therapeutics (NYSEAMERICAN:LCTX) Trading 13.7% Higher - Should You Buy?July 24, 2025 | marketbeat.comLineage Cell Therapeutics Inc. Stock Grades | LCTX | Barron'sJuly 18, 2025 | barrons.comLineage Cell Therapeutics Inc. - LCTX | Barron'sJuly 18, 2025 | barrons.comLineage Cell Therapeutics shareholders approve board slate and equity plan amendment - Investing.comJuly 4, 2025 | investing.comLineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) Shares Acquired by Defender Capital LLC.July 2, 2025 | marketbeat.comLCTX Lineage Cell Therapeutics, Inc. - Seeking AlphaJune 27, 2025 | seekingalpha.comLineage Cell Therapeutics (AMEX:LCTX) Stock, Short Interest ReportJune 23, 2025 | benzinga.comLineage Cell Therapeutics (AMEX:LCTX) Stock, Insider Trading ActivityJune 23, 2025 | benzinga.comLineage Cell Therapeutics Earnings Estimates, EPS & Revenue | AMEX:LCTX | BenzingaJune 23, 2025 | benzinga.comD. Boral Capital Reaffirms "Buy" Rating for Lineage Cell Therapeutics (NYSEAMERICAN:LCTX)June 23, 2025 | marketbeat.comLineage Cell Therapeutics (NYSEAMERICAN:LCTX) Earns Buy Rating from HC WainwrightJune 23, 2025 | marketbeat.comOpRegen® (RG6501) 36-Month Visual Acuity Results Featured at Clinical Trials at the Summit 2025June 23, 2025 | businesswire.comLineage Cell Therapeutics appoints new auditorJune 11, 2025 | investing.comLineage Cell Therapeutics Announces Updates to the 3rd Annual Spinal Cord Injury Investor SymposiumJune 5, 2025 | finance.yahoo.comB. Riley Predicts Lineage Cell Therapeutics FY2029 EarningsMay 27, 2025 | marketbeat.comLineage Cell Therapeutics at H.C. Wainwright: Strategic Insights on OpRegenMay 21, 2025 | investing.comJacobs Levy Equity Management Inc. Purchases Shares of 1,033,763 Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX)May 20, 2025 | marketbeat.comComerica Bank Boosts Position in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX)May 18, 2025 | marketbeat.comLineage Cell Therapeutics’ Earnings Call Highlights Progress and ChallengesMay 15, 2025 | tipranks.comLineage to Present at 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYCMay 14, 2025 | businesswire.comLineage Cell Therapeutics, Inc. (LCTX) Q1 2025 Earnings Call TranscriptMay 13, 2025 | seekingalpha.comLineage Cell Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 13, 2025 | businesswire.comExamining the Future: Lineage Cell Therapeutics's Earnings OutlookMay 12, 2025 | benzinga.comRG6501 (OpRegen®) Phase 1/2a Clinical Study 36 Month Results to Be Featured at Clinical Trials at the Summit 2025May 12, 2025 | businesswire.comDAFNA Capital Management LLC Raises Stock Position in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX)May 10, 2025 | marketbeat.comAlyeska Investment Group L.P. Takes Position in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX)May 9, 2025 | marketbeat.comLineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) Shares Purchased by Raffles Associates LPMay 3, 2025 | marketbeat.comLineage Cell Therapeutics (LCTX) to Release Earnings on ThursdayMay 3, 2025 | marketbeat.comLineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) Shares Bought by Renaissance Technologies LLCMay 2, 2025 | marketbeat.comLineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) Sees Large Increase in Short InterestApril 23, 2025 | marketbeat.comLineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 3rd Annual Spinal Cord Injury Investor SymposiumApril 22, 2025 | businesswire.comLineage to Present at 2025 Eyecelerator Meeting Sponsored by the American Academy of Ophthalmology (AAO)April 21, 2025 | finance.yahoo.comLineage Cell Therapeutics (NYSEAMERICAN:LCTX) Shares Down 7.4% - Here's What HappenedApril 10, 2025 | marketbeat.comMaxim Group Reaffirms Their Buy Rating on Lineage Therap (LCTX)April 5, 2025 | markets.businessinsider.comB. Riley Forecasts Lineage Cell Therapeutics Q1 EarningsMarch 17, 2025 | marketbeat.comB. Riley Issues Pessimistic Forecast for Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Stock PriceMarch 15, 2025 | marketbeat.comHC Wainwright Weighs in on Lineage Cell Therapeutics Q1 EarningsMarch 14, 2025 | marketbeat.comBeyond The Numbers: 7 Analysts Discuss Lineage Cell Therapeutics StockMarch 13, 2025 | nasdaq.comLineage Cell Therapeutics (NYSEAMERICAN:LCTX) Receives Buy Rating from HC WainwrightMarch 12, 2025 | marketbeat.comLineage Cell Therapeutics Faces Uncertainty Amid New U.S. Administration’s PoliciesMarch 12, 2025 | tipranks.com Get Lineage Cell Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LCTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LCTX Media Mentions By Week LCTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LCTX News Sentiment▼0.201.03▲Average Medical News Sentiment LCTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LCTX Articles This Week▼21▲LCTX Articles Average Week Get the Latest News and Ratings for LCTX and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Lineage Cell Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies LENZ Therapeutics News Zymeworks News Sionna Therapeutics News Arcus Biosciences News Structure Therapeutics News Cybin News Stoke Therapeutics News True Drinks News CorMedix News Nuvation Bio News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSEAMERICAN:LCTX) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lineage Cell Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lineage Cell Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access